Real-world study links acoramidis to improved ATTR-CM outcomes
A propensity score-matched analysis of 2,684 people with ATTR-CM found acoramidis was associated with an 18% lower risk of a composite outcome than tafamidis. The supplied report truncates before listing all components.
Story updates
06:32:58 PM UTC
SquawkNews
BridgeBio reported an independent EHR study in 2,684 ATTR-CM patients where acoramidis was associated with an 18% lower risk of a composite outcome vs. tafamidis (HR 0.82; p<0.01) and ~25—27% lower hospitalization risks (all p<0.001).Material DetailsContext by AI AnalystThis builds on ATTRibute-CM…